Excellent point. And the FDA's(s) counter to your surrogate endpoint statement is probably based on original (and likely outdated) research showing that the plaques were primarily found in Alzheimer's patients therefore if a drug reduces plaques it must be good...(sure, ok I believe them). Follow the money trail.